Navigation Links
APA Comments on FDA's First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
Date:9/3/2007

ARLINGTON, Va., Aug. 22 /PRNewswire-USNewswire/ -- The American Psychiatric Association (APA) applauds the U.S. Food and Drug Administration (FDA) for its review of scientific evidence that led to the approval of a new treatment for two severe psychiatric disorders in children. The APA is pleased that the approvals are a result of the federal Best Pharmaceuticals for Children Act (BCPA), which was designed to encourage research that leads to this kind of approval, given that dosages, side effects and efficacy can vary significantly with children.

"Schizophrenia and bipolar disorder are severely disabling to patients and devastating to their families," said APA President Carolyn Robinowitz, M.D. "For many children suffering with psychiatric illnesses, medications are an important part of a comprehensive treatment program, which should include talk therapy and other interventions."

"For any medication there are benefits and potential risks," said Darrel Regier, M.D., M.P.H., director, APA Division of Research, and executive director, American Psychiatric Institute for Research and Education. "For many children with these disorders, the FDA's action today provides additional information to guide treatment options in these special populations. We anticipate that approval of this medication will encourage federal research agencies to accelerate urgently needed studies of mental disorders in children."

Physicians and parents must work together to evaluate the risks and benefits of any particular treatment. The APA recommends that all treatment for psychiatric illnesses are guided by a thorough evaluation and careful diagnosis, followed up with a treatment plan tailored to the needs of the child and the family.

About the American Psychiatric Association:

The American Psychiatric Association is a national medical specialty society whose more than 38,000 physician members specialize in diagnosis, treatment, prevention and research of mental illnesses including substance use disorders. Visit the APA at http://www.psych.org and http://www.HealthyMinds.org.

For Information Contact:

Lydia Sermons-Ward, 703-907-8640

press@psych.org

Alissa Schulman, 703-907-8562

aschulman@psych.org


'/>"/>
SOURCE American Psychiatric Association
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Northfield Labs Receives FDA Comments
2. FDAs Failure Urges It to Reassess Its Policies
3. FDAs Gesture for Firm Manufacturing Drug for Cushings Syndrome
4. First Vaccine Designed for Africa Cleared for Testing in Humans
5. Infant receives first bloodless liver transplant
6. Oracle Corp. to help build worlds first "Digital Hospital"
7. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
8. First human clone is near
9. First Artificial Heart patient has Major setback
10. First global SARS meet opens
11. Launch Of India’s First Virology Course At Pun
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider of ... that Kyle Allain has joined the company as Vice President and General Manager ... provider, payor and managed care solutions. , A seasoned executive with more ...
(Date:4/24/2017)... ... April 24, 2017 , ... In ... be diagnosed globally; approximately 25,000 of them will be malignant.(1) As research into ... this type of healthcare model in the diagnosis and treatment of brain tumors. ...
(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of Gardant ... website. , Rod has been at the forefront of Gardant since it was founded ... Rod has overseen the opening of more than 40 new senior living communities. With ...
(Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel known for her ... good news for single women is that she put all the words in her ... 25th. Joan's insight, personal experiences and sparkling sense of humor have inspired her to ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... familiar. This makes it difficult for lab operators and management to assess these ... help them identify wasteful or unnecessary actions. , Created with the help ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology: